Flavio Matassoli

Flavio Matassoli

Auto-generated profile, based on publicly available information

Flavio Matassoli

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
MPMadhu Prabhakaran
Madhu Prabhakaran
FMFlavio Matassoli
Flavio Matassoli
DLDavid Leggat
David Leggat
AHAbigayle Hoover
Abigayle Hoover
ASAbhinaya Srikanth
Abhinaya Srikanth
AMAdrian B. McDermott
Adrian B. McDermott
Durable humoral immunity is mediated by long-lived plasma cells (LLPCs) that reside in the bone marrow. It remains unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein vaccination is able to elicit and maintain LLPCs. Here, we describe a sensitive method to identify and isolate antigen-specific LLPCs by tethering antibodies secreted by these cells onto the cell surface. Using this method, we found that two doses of adjuvanted SARS-CoV-2 spike protein vaccination are able to induce spike protein–specific LLPC reservoirs enriched for receptor binding domain specificities in the bone marrow of nonhuman primates that are detectable for several months after vaccination. Immunoglobulin gene sequencing confirmed that several of these LLPCs were clones of memory B cells elicited 2 weeks after boost that had undergone further somatic hypermutation. Many of the antibodies secreted by these LLPCs also exhibited improved neutralization and cross-reactivity compared with earlier time points. These findings establish our method as a means to sensitively and reliably detect rare antigen-specific LLPCs and demonstrate that adjuvanted SARS-CoV-2 spike protein vaccination establishes spike protein–specific LLPC reservoirs.

19 May 2016 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CLCarolina G. D. O. Lucas
Carolina G. D. O. Lucas
FMFlavio L. Matassoli
Flavio L. Matassoli
LPLigia M. T. Peçanha
Ligia M. T. Peçanha
BSBruna Tereso Santillo
Bruna Tereso Santillo
LOLuanda Oliveira
Luanda Oliveira
LALuciana Arruda
Luciana Arruda
The decline in number and function of T cells is a hallmark of HIV infection, and preservation or restoration of HIV‐specific cellular immune response is a major goal of AIDS treatment. Dendritic cells (DCs) play a key role in the initiation and maintenance of the immune response, and their use as a vaccine vehicle is a promising strategy for enhancing vaccine efficacy. We evaluated the potential of DC‐mediated immunization with a DNA vaccine consisting of HIV‐1‐p55gag (gag, group‐specific antigen) associated to lysosomal associated protein (LAMP) sequence (LAMP/ gag vaccine). Immunization of mice with mouse DCs transfected with LAMP/gag (Lg‐mDCs) stimulated more potent B‐ and T‐cell responses than naked DNA or DCs pulsed with inactivated HIV. Anti‐Gag antibody levels were sustained for at least 3 mo after immunization, and recall T‐cell responses were also strongly detected at this time point. Human DCs transfected with LAMP/ gag (Lg‐hDCs) were also activated and able to stimulate greater T‐cell response than native gag ‐transfected DCs. Coculture between Lg‐hDCs and T lymphocytes obtained from patients with HIV resulted in upregulation of CD38, CD69, HLA‐DR, and granzyme B by CD4 + and CD8 + T cells, and increased IFN‐γ and TNF‐α production. These results indicate that the use of LAMP/ gag ‐DC may be an efficient strategy for enhancing immune function in patients with HIV.—Lucas, C. G. D. O., Matassoli, F. L., Peçanha, L. M. T., Santillo, B. T., Oliveira, L. M. D. S., Oshiro, T. M., Marques, E. T. D. A., Jr., Oxenius, A., de Arruda, L. B. Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/ gag ) is a potential therapeutic vaccine against HIV. FASEB J. 30, 2970‐2984 (2016). www.fasebj.org

10 June 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
RMRory Malek
Rory Malek
FMFlavio Matassoli
Flavio Matassoli
KGKyle Gordon
Kyle Gordon
GSGeoffrey D. Shimberg
Geoffrey D. Shimberg
GMGrace E. Mantus
Grace E. Mantus
SASarah F. Andrews
Sarah F. Andrews
Evolving endemic viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain major health threats. Although variant updated vaccines aim to enhance protection, preexisting immunity shapes memory B cell (MBC) responses. To assess how SARS-CoV-2 spike protein variant–based vaccine boosters and infections alter the MBC repertoire, we analyzed MBC responses in the COVAIL vaccine trial, where participants previously vaccinated with SARS-CoV-2 Wuhan-1 spike immunogen were boosted with Wuhan-1, variant, or bivalent spike immunogens. Some participants also experienced a subsequent infection with an Omicron variant. We determined that variant vaccine boosters and SARS-CoV-2 infections led to transiently greater recall of cross-reactive MBCs compared with a Wuhan-1 vaccine booster. Long term, we detected little change in the MBC repertoire after an Omicron vaccine booster, but MBCs evaluated several months after Omicron variant infection had higher neutralization capacity to both Wuhan-1 and BA.1 compared with those from individuals who had not experienced an infection. However, these Wuhan-1/BA.1 cross-reactive MBCs from infected individuals displayed less breadth toward the more distant BA.2.86 lineage than MBCs from uninfected individuals. Thus, SARS-CoV-2 variant boosters and infections differentially shape the long-term MBC repertoire.

13 August 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
BBBruno Braz Bezerra
Bruno Braz Bezerra
KMKeylla Vitória Gomes Macedo
Keylla Vitória Gomes Macedo
ICIsadora Alonso Correa
Isadora Alonso Correa
Sharton Vinicius Antunes CoelhoSharton Vinicius Antunes Coelho
Sharton Vinicius Antunes Coelho
MSMarcos Romario Matos de Souza
Marcos Romario Matos de Souza
LALuciana Arruda
Luciana Arruda
Hydroxypropyl-beta-cyclodextrin (HP-BCD) is a cholesterol sequestering agent that has been explored as a potential antiviral drug against enveloped viruses and is currently under clinical investigation for Niemann Pick C disease. We previously demonstrated that HP-BCD inhibits SARS-CoV-2 replication and infectivity by targeting both host cells and viral particles. In this study, we investigated the molecular mechanisms underlying HP-BCD antiviral activity against SARS-CoV-2 in vitro. Treatment of Vero cells with HP-BCD altered intracellular compartmentalization, as indicated by the redistribution of early endosome markers. Also, HP-BCD treatment prior to SARS-CoV-2 inoculation promoted an accumulation of nucleocapsid protein at early time points after infection. Infected cells pretreated with HP-BCD exhibited reduced cholesterol and lipid droplets content, potentially hampering the formation of new double-membrane vesicles. Consistently, viral replication complexes were scarcely detected in treated cells, which displayed disformed vesicle-like structures and lacked membrane-associated virus particles. Notably, HP-BCD also reduced viral replication when administered after virus adsorption, although with lower efficacy, indicating interference with potentially multiple stages of the SARS-CoV-2 life cycle. These findings suggest that HP-BCD effectively impairs SARS-CoV-2 biosynthesis through multiple mechanisms with minimal cytotoxicity, supporting its potential as a promising antiviral candidate.